Loading
SPRY4 is a feedback brake on growth-factor signalling that the MAPK pathway switches on, so its expression is a read-out of how active that pathway is. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Suppresses insulin receptor and EGFR-transduced MAPK signalling, probably by impairing GTP-Ras formation; inhibits Ras-independent activation of RAF1 (UniProt Q9C004).
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
The resistance atlas has no route that names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"SPRY4" OR ABSTRACT:"SPRY4" OR TITLE:"sprouty RTK signaling antagonist 4" OR ABSTRACT:"sprouty RTK signaling antagonist 4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SPRY4, not a curated reading list.
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/spry4.json. Licence CC BY-NC 4.0.